0001209191-19-002668.txt : 20190107 0001209191-19-002668.hdr.sgml : 20190107 20190107203346 ACCESSION NUMBER: 0001209191-19-002668 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190103 FILED AS OF DATE: 20190107 DATE AS OF CHANGE: 20190107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Stephen R CENTRAL INDEX KEY: 0001606241 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36561 FILM NUMBER: 19514524 MAIL ADDRESS: STREET 1: C/O IMMUNE DESIGN CORP. STREET 2: 1616 EASTLAKE AVE. E, SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNE DESIGN CORP. CENTRAL INDEX KEY: 0001437786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262007174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE E. STREET 2: SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (650) 392-8350 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Immune Design Corp. DATE OF NAME CHANGE: 20090702 FORMER COMPANY: FORMER CONFORMED NAME: VACCSYS INC DATE OF NAME CHANGE: 20080617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-03 0 0001437786 IMMUNE DESIGN CORP. IMDZ 0001606241 Brady Stephen R C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102 0 1 0 0 EVP, Strategy & Finance Common Stock 2019-01-03 4 A 0 25000 0.00 A 102115 D Common Stock 2019-01-07 4 S 0 5516 1.5812 D 96599 D Stock Option (right to buy) 1.31 2019-01-03 4 A 0 120000 0.00 A 2029-01-03 Common Stock 120000 120000 D Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date. The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016, January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.62 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. /s/ Stephen R. Brady 2019-01-07